TCRTNasdaqPharmaceutical PreparationsFiscal year ends December 31

Alaunos Therapeutics, Inc.

Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 14, 2026

$3.13+0.50 (+19.01%)

Close on Oct 19, 2026

Market cap: $7.61M
P/E (TTM): –
Dividend yield: –

Alaunos Therapeutics, Inc. income statement

Annual Quarterly TTM

Millions of USD, except per-share data. Shares in millions.

Line item	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31	FY 2020 2020-12-31	FY 2019 2019-12-31	FY 2018 2018-12-31	FY 2017 2017-12-31	FY 2016 2016-12-31	FY 2015 2015-12-31	FY 2014 2014-12-31	FY 2013 2013-12-31	FY 2012 2012-12-31	FY 2011 2011-12-31	FY 2010 2010-12-31	FY 2009 2009-12-31	FY 2008 2008-12-31	FY 2007 2007-12-31	FY 2006 2006-12-31
Revenue	0.01	0.01	0.01	2.92	0.40	0	–	0.15	16	6.86	–	–	–	0.80	0.67	–	–	–	–	–
Research & Development	1.36	0.36	16	25	50	53	38	34	45	158	107	33	43	83	57	13	4.56	–	–	–
General & Administrative	2.87	4.46	12	13	28	28	20	20	15	14	18	12	16	20	15	12	7.57	–	–	–
Operating Expenses	4.23	4.82	34	38	78	80	58	54	60	–	–	–	–	–	–	–	–	–	–	–
Operating Income	-4.23	-4.81	-34	-35	-78	-80	-58	-54	-53	-165	-120	-43	-58	-102	-71	-25	-12	–	–	–
Interest Expense	–	0	1.92	3.15	1.19	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Other Non-Operating Income	0.05	0.13	-0.87	-2.63	-1.20	0.39	0.81	0.63	0.47	0.13	0.01	-0.01	-0.58	-0.01	0.04	0.77	0.01	–	–	–
Merger & Restructuring Charges	–	0	1.27	0	–	–	–	–	–	–	–	–	1.70	–	–	–	–	–	–	–
Asset Impairment Charges	–	0	4.80	0	0.74	0	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Gain (Loss) on Sale of Assets	–	0	-0.01	-0.01	0	–	–	–	–	–	–	–	-0.60	-0.05	0	–	–	–	–	–
Income Tax Expense	0	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Net Income	-4.18	-4.68	-4.68	-38	-79	-80	-118	-53	-54	-165	-120	-32	-57	-96	-64	-33	-7.65	-25	-27	-18
Preferred Dividends	–	–	–	–	–	–	–	17	19	7.12	–	–	–	–	–	–	–	–	–	–
Net Income to Common	-4.28	-4.68	–	–	-79	-80	-118	137	-73	-172	-120	-32	–	–	–	–	–	–	–	–
EPS (Basic)(per share)	-2.20	-2.92	-21.97	-26.10	-55.50	-57.00	-105.00	144.00	-79.50	-198.00	-144.00	-46.50	-99.00	-183.00	-145.50	-106.50	-49.50	–	–	–
EPS (Diluted)(per share)	-2.20	-2.92	-21.97	-26.10	-55.50	-57.00	-105.00	144.00	-79.50	-198.00	-144.00	-46.50	-99.00	-183.00	-145.50	-106.50	-49.50	–	–	–
Shares Outstanding (Basic, Weighted)(shares)	1.95	1.60	1.60	1.45	1.43	1.40	1.12	0.96	0.91	0.87	0.84	0.67	0.57	0.52	0.44	0.31	–	–	–	–
Shares Outstanding (Diluted, Weighted)(shares)	1.95	1.60	1.60	1.45	1.43	1.40	1.12	0.96	0.91	0.87	0.84	0.67	0.57	0.52	0.44	0.31	–	–	–	–
EBITDA	–	–	–	–	–	–	–	–	–	-165	-120	-43	-57	-102	-71	-24	-12	–	–	–

Italic numbers are calculated by StockData (for example Q4 = full year − nine months). Per-share data and share counts are adjusted for stock splits. Hover a number for its source; click it to open the filing on SEC.gov. Click a row to chart it.

Ratios

Latest available, balances at Jun 30, 2026

Profitability, TTM

Gross margin: –
Operating margin: -135266.7%
Net margin: -133666.7%
Return on equity, FY2025: -198.1%

Financial strength

Current ratio: 0.77
Debt to equity: –
Debt to assets: –
Cash to current liabilities: 14.4%

Valuation

P/E ratio: –
Price to sales: 2537.07
Price to book: 11.67
Dividend yield: –